Research analysts at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.
NanoViricides Stock Performance
NNVC stock opened at $1.20 on Wednesday. NanoViricides has a 52 week low of $1.00 and a 52 week high of $2.00. The company has a market capitalization of $14.14 million, a PE ratio of -1.48 and a beta of 0.68. The company’s 50-day simple moving average is $1.21 and its 200 day simple moving average is $1.16.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Stories
- Five stocks we like better than NanoViricides
- Industrial Products Stocks Investing
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Options Trading – Understanding Strike Price
- Hilton Demonstrates Asset Light is Right for Investors
- Insider Trades May Not Tell You What You Think
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.